Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer
Last Updated: Friday, July 17, 2026
In a cohort study of 54,953 older men with prostate cancer, only 7.9% received dual-energy x-ray absorptiometry (DXA) screening within 12 months before and 6 months after beginning androgen-deprivation therapy. However, testing of bone mineral density with DXA was significantly associated with a decreased risk of developing major osteoporotic fractures (HR, 0.91; 95% CI, 0.83-1.00; P = .05) after adjusting for propensity score.
